BCA101,Pembrolizumab
Bicara,Merck
['head and neck', 'keytruda', '$mrk', 'bicara']
#asco23 bicara's impressive data in head and neck cancer (48% orr, 65% in hpv negative disease) potential beats keytruda, and has the private group making pivotal plans. i spoke to ceo claire mazumdar: $mrk
Pharma and biotech reporter, found a home at Evaluate Vantage.